… Small-cell lung cancer (SCLC) is an aggressive tumor type … that the addition of pembrolizumab
to chemotherapy failed to … and pembrolizumab single agents showed anti-tumor activity …

… the rationale for using immunotherapy in SCLC and provides an overview of the
immunotherapeutic agents under clinical investigation for SCLC. Rationale for immunotherapy in …

… Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly poor
… These results quickly established chemo-immunotherapy as the preferred initial treatment …

… This review discusses the rationale for immunotherapy and provides an overview of the
immunotherapeutic agents under … Small cell lung cancer: where do we go from here? …

… Immunotherapies … immunotherapies in patients with small-cell lung cancer include
immune-checkpoint inhibitors (anti-programmed cell death protein 1 (PD-1), anti-programmed cell …

… with immune-checkpoint inhibitors (nivolumab and pembrolizumab) has been approved by
… for non-small-cell lung cancer (NSCLC), melanoma, and renal-cell carcinoma. Might the …

… Immunecheckpoint inhibition is a form of anti-cancer immunotherapy that targets key regulators
… Current standards for clinical management of small cell lung cancer. Transl Lung Cancer …

… Small cell lung cancer (SCLC) is a poorly differentiated and high-grade … tumor, which
accounts for 10%−15% of all lung cancers (1,2). SCLC is characterized by short tumor doubling …

… results of immunotherapy in melanoma, lung cancer came into … in clinical trials in non-small
cell lung cancer (NSCLC) for … 15% of all lung cancers are small cell lung cancers (SCLCs) …

… In the manuscript we review molecular rationale for immunotherapy treatment, for synergism
with chemotherapy and for other potential combination treatment including immunotherapy. …